All countries
All categories
Compare
Add to selected
Share   ID: 91374:698559
Buy Zelboraf 240mg
0UAHGet latest price
Description
  • BrandZelboraf 240mg
Product Name: Zelboraf 240mg
Product Type: Tablets
Strength: 240 mg
These tablets are processed using high grade ingredients. This medician is used for cancer.

Features:

  • Long shelf life
  • Effective
  • Purity
Supplied As:

240mg

Overdose:

There is no specific antidote for overdose of vemurafenib. Patients who develop adverse reactions should receive appropriate symptomatic treatment. No cases of overdose have been observed with vemurafenib in clinical trials. In case of suspected overdose, vemurafenib should be withheld and supportive care initiated.

Precaution And Warning:

Before taking vemurafenib, patients must have BRAF V600 mutation-positive tumour status confirmed by a validated test. The efficacy and safety of vemurafenib in patients with tumours expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established (see section 5.1). Vemurafenib should not be used in patients with wild type BRAF malignant melanoma.

Hypersensitivity reaction

Serious hypersensitivity reactions, including anaphylaxis have been reported in association with vemurafenib. Severe hypersensitivity reactions may include Stevens-Johnson syndrome, generalised rash, erythema or hypotension. In patients who experience severe hypersensitivity reactions, vemurafenib treatment should be permanently discontinued.

Dermatologic reactions

Severe dermatologic reactions have been reported in patients receiving vemurafenib, including rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis in the pivotal clinical trial. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in association with vemurafenib in the post marketing setting . In patients who experience a severe dermatologic reaction, vemurafenib treatment should be permanently discontinued.

Potentiation of radiation toxicity

Cases of radiation recall and radiation sensitization have been reported in patients treated with radiation either prior, during, or subsequent to vemurafenib treatment. Most cases were cutaneous in nature but some cases involving visceral organs had fatal outcomes.

Vemurafenib should be used with caution when given concomitantly or sequentially with radiation treatment.

QT prolongation

Exposure-dependent QT prolongation was observed in an uncontrolled, open-label phase II study in previously treated patients with metastatic melanoma QT prolongation may lead to an increased risk of ventricular arrhythmias including Torsade de Pointes. Treatment with vemurafenib is not recommended in patients with uncorrectable electrolyte abnormalities (including magnesium), long QT syndrome or who are taking medicinal products known to prolong the QT interval.

Ophthalmologic reactions

Serious ophthalmologic reactions, including uveitis, iritis and retinal vein occlusion, have been reported. Monitor patients routinely for ophthalmologic reactions.

Cutaneous Squamous Cell Carcinoma

It is recommended that all patients receive a dermatologic evaluation prior to initiation of therapy and be monitored routinely while on therapy. Any suspicious skin lesions should be excised, sent for dermatopathologic evaluation and treated as per local standard of care. The prescriber should examine the patient monthly during and up to six months after treatment for cuSCC. In patients who develop cuSCC, it is recommended to continue the treatment without dose adjustment. Monitoring should continue for 6 months following discontinuation of vemurafenib or until initiation of another anti-neoplastic therapy.

Photos
  • Zelboraf 240mg
  • Would you like to see more pictures?

    Send inquiry
Buy zelboraf 240mg
Order
Get latest price
Or contact the seller
Try to describe briefly the essence of your question to the seller (at least 20 symbols)
Go backin section "Anti Cancer Medicines"
for
by the goods
Your message must contain at least 20 symbols. The message must not be more than 2000 symbols.
Obligatory field is not filled
The field is wrongly filled
The field is wrongly filled
Compare0
ClearSelected items: 0